Our findings on FOXM1-driven expression of glucose import (GLUT1) and glycolytic pathway genes (HK2, LDHA) in OPM2 and Delta47 cells extend published work on the transcriptional regulation of glycolysis in myeloma and suggest that co-inhibition of FOXM1 and glycolysis affords a new treatment approach (Fig. 8E). The gene discussed is FOXM1; the disease is plasma cell myeloma.